|
TUESDAY, DECEMBER 6, 2022 |
| All times are CENTRAL Time |
|
|
| |
|
|
| 8:00 am - 9:45 am CT |
Clinical Research Workshop - Stars at Night Ballroom 1&2
Moderator: Aditya Bardia, MD, MPH
Massachusetts General Hospital Cancer Center
Boston, MA
Use of the postneoadjuvant setting to accelerate drug development
Melinda Telli, MD
Stanford University School of Medicine
San Francisco, CA
How to measure and improve drug adherence in clinical trials
Dawn L. Hershman, MD, MS, FASCO
Columbia University
New York, NY
Statistical considerations for precision medicine
Nabihah Tayob, PhD
Dana-Farber Cancer Institute
Boston, MA
Bringing clinical trials to all patients: A patient's perspective
Thelma Brown, BSc
University of Alabama at Birmingham
Birmingham, AL
|
|
| 8:00 am - 9:45 am CT |
|
Basic Science Workshop - Stars at Night Ballroom 3&4
Moderator: Alana L. Welm, PhD
University of Utah
Salt Lake City, UT
Drug-tolerant persister cells in cancer
Joan S. Brugge, PhD
Harvard Ludwig Cancer Center
Boston, MA
APOBEC and genome evolution in mBC
Reuben S. Harris, PhD
UT Health San Antonio
San Antonio, TX
Therapy-induced senescence: Friend or foe?
Sheila Stewart, PhD
Washington University School of Medicine
St. Louis, MO
Clinical implications of tumor heterogeneity single cell genomics
Nnennaya Kanu, PhD
University College London
London, United Kingdom
|
|
| 9:45 am - 10:00 am CT |
Break |
|
| 10:00 am - 12:00 pm CT |
EDUCATIONAL SESSION BLOCK #1
Educational Session Block #1A - Stars at Night Ballroom 3&4
Living with Metastatic Breast Cancer
Moderator: Anne Blaes, MD
University of Minnesota
Minneapolis, MN
Early palliative care
Tara L. Kaufmann, MD, MSCE
UT Health Austin
Austin, TX
Support for patients with MBC
Abbey Kaler, MS, APRN, FNP-C
UT MD Anderson Cancer Center
Houston, TX
Financial Toxicity
Fumiko Chino, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Patient Perspective
Christine Hodgdon, MS
GRASP - Guiding Researchers & Advocates to Scientific Partnerships
Baltimore, MD
Stephanie Walker, BSN
MBC Alliance
Tarboro, NC
EDUCATIONAL SESSION BLOCK #1B - Hemisfair Ballroom 1&2
Local Therapy - Best Breast Practice
Moderator: Peter Dubsky, MD, PhD
Breast Center Hirslanden Klinik St. Anna
Zurich, Switzerland
Contralateral mastectomy in patients with germline mutations
Katharine A. Yao, MD
Northshore Medical Group
Evanston, IL
RT: How short can it be
David Krug, Dr Med
Universitätsklinikum Schleswig-Holstein
Kiel, Germany
How to reconcile novel reconstructive techniques with the need to radiate
Christine Solbach, MD, PhD
University Hospital Frankfurt
Frankfurt, Germany
EDUCATIONAL SESSION BLOCK #1C - Hemisfair Ballroom 3
New Agents Targeting HRD in Breast Cancer
Moderator: Erica Stringer-Reasor, MD
University of Alabama at Birmingham
Birmingham, AL
Pol-theta inhibitors in HRD tumors
Alan D. d'Andrea, MD
Dana-Farber Cancer Institute
Boston, MA
Mechanisms of sensitivity and resistance to HRD targeting agents in breast cancer - PARPi and beyond
Christopher Lord, DPhil
Institute of Cancer Research
London, United Kingdom
ATR inhibitors and PARP1 selective PARP inhibitors
Andrew Tutt, MB ChB, MRCP, FRCR, PhD
Institute of Cancer Research
London, United Kingdom
EDUCATIONAL SESSION BLOCK #1D - Stars at Night Ballroom 1&2
Predictive Value of Treatment Response and Residual Disease After Neoadjuvant Therapy
Moderator: Virginia Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Hormone receptor positive breast cancer
Cynthia X. Ma, MD, PhD
Washington University in St. Louis
St. Louis, MO
HER2 positive breast cancer
Luca Gianni, MD
Fondazione Michelangelo
Milano, Italy
Triple negative breast cancer
Peter Schmid, MD, PhD
Bart's Cancer Institute
London, United Kingdom
|
|
| 12:00 pm - 2:00 pm CT |
SPECIAL SESSION #1 - Stars at Night Ballroom 1&2
Big Data and Health Equity
This presentation meets the Texas Medical Board criteria for formal continuing medical education involving the study of medical ethics and/or professional responsibility.
Moderators: Thelma Brown, BSc
University of Alabama at Birmingham
Birmingham, AL
Maimah Karmo, BS
Tigerlily Foundation
Aldie, VA
Charles Perou, PhD
University of North Carolina
Chapel Hill, NC
Keynote Speakers:
Martin Mendoza, PhD
National Institutes of Health
Bethesda, MD
Barbara Seggara, D.H.Sc
University of Puerto Rico
San Juan, Puerto Rico
Panelists:
Rea Blakey
FDA
Silver Spring, MD
Michael Crawford, MBA, MHLA
Howard University
Washington, DC
Andrea Downing
The Light Collective
Shoreline, WA
Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN
Charlotte Owens, MD
Takeda Pharmaceutical Company
Cambridge, MA
Jasmine Souers, BSc
The Missing Pink Breast Cancer Alliance
Jackson, FL
|
|
|
12:00 pm Welcome and Introduction of Topic
12:10 pm Keynote Speaker #1 - Martin Mendoza
12:30 pm Panel 1: The use of data to provide services to specific populations, telemedicine, virtual clinical trials
1:00 pm Speaker Introduction
1:05 pm Keynote Speaker #2 - Barbara Seggara
1:25 pm Panel 2: Patient privacy & use of data to provide services
1:55 pm Closing Remarks |
|
| 12:00 pm - 2:00 pm CT |
SPECIAL SESSION #2 - Hall 3
Overcoming the Big Obstacles to Find Solutions for Breast Cancer
Chairs: Carlos Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
and
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA
Panelists:
Christine Ambrosone, PhD
Roswell Park Comprehensive Cancer Center
Buffalo, NY
Fabrice André, MD, PhD
Gustave Roussy
Villejuif, France
Regina Barzilay, PhD
Massachusetts Institute of Technology
Cambridge, MA
Joan S. Brugge, PhD
Harvard Ludwig Cancer Center
Boston, MA
Matthew J. Ellis, MB, BChir, BSc, PhD, FRCP
AstraZeneca
Washington, DC
Nadia Harbeck, MD, PhD
University of Munich
Munich, Germany
Yeon Hee Park, MD, PhD
Samsung Medical Center
Seoul, Republic of Korea
Lori Pierce, MD
University of Michigan
Ann Arbor, MI
Patty Spears, BS
University of North Carolina
Chapel Hill, NC
Eric Winer, MD
Yale Cancer Center
New Haven, CT
|
|
|
12:00 pm Introduction
12:10 pm Prevention, Early Detection, and Interception
12:27 pm Underutilization
of AI/big data/digital transformation
12:44 pm Precision Oncology:
Omics Not Used Widely Enough
1:01 pm Clinical
Trials Process – Need for Innovation
1:18 pm Cancer Health
Disparities
1:35 pm Aligning
Incentives and Funding for Collaboration, Training and Retention
1:55 pm Summary & Closing Statements (DeMichele & Arteaga)
|
|
| 2:00 pm - 5:00 pm CT |
GENERAL SESSION #1 - Hall 3
Moderator: Shom Goel, MBBS, B Med Sci (Hons)
Peter MacCallum Cancer Centre
Melbourne, Australia
Ann Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
|
|
| 2:00 pm - 2:15 pm CT |
GS1-01 Race and clinical outcomes in the RxPONDER trial (SWOG S1007)
Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SK, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K. University of North Carolina; SWOG Statistics and Data Management Center; ASCO; The University of Texas MD Anderson Cancer Center, Houston, TX; Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center; University of Michigan Comprehensive Cancer Center; Medical Oncology, Dana-Farber Cancer Institute; Susan F. Smith Center for Women's Cancers, Dana-Farber Brigham Cancer Center; Harvard Medical School; Mayo; Fox Chase Cancer Center; British Columbia Cancer Agency, Vancouver, BC, Canada; Juravinski Cancer Centre at Hamilton Health Sciences; UPMC Hillman Cancer Center and NRG Oncology; Hospital Regional Universitario y Virgen de la Victoria, Málaga, Andalucia, Spain; Institut Gustave Roussy, Villejuif, France; Rogel Cancer Center, University of Michigan Health, Ann Arbor, MI; Exact Sciences; University of Kansas Medical Center Westwood, Westwood, KS, USA; Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Center; The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Yale University Cancer Center, New Haven, CT, USA; Winship Cancer Institute at Emory University, Atlanta, GA, USA. |
|
| 2:15 pm - 2:30 pm CT |
GS1-02 Racial disparity in tumor microenvironment and outcomes in residual breast cancer treated with neoadjuvant chemotherapy
Karadal B, Kim G, Sharma V, Pastoriza J, Oktay I, Lin Y, Ye X, Qin J, Cheng E, Ladak N, Condeelis J, Adler E, Ginter P, D'Alfonso T, Xue X, Enterberg D, Sparano J, Oktay M. Albert Einstein College of Medicine; Montefiore Medical Center; The Rockefeller University; New York University; CBL Pathology; NYU Grossman School of Medicine; NYU Long Island School of Medicine, Memorial Sloan Kettering Cancer Center; Mount Sinai Health System, New York, NY, USA. |
|
| 2:30 pm - 2:45 pm CT |
GS1-03 Discussant for GS1-01 and GS1-02
Lori Pierce, MD
University of Michigan
Ann Arbor, MI |
|
| 2:45 pm - 3:00 pm CT |
GS1-04 Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status
Kang I, Forschmiedt JK, Loch MM, Barlow WE, Lew DL, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Miao J, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K, Henry NL. University of Southern California; Fred Hutchinson Cancer Center; LSUHSC, New Orleans; SWOG Statistics and Data Management Center; Fred Hutchinson Cancer Research Center; ASCO; The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center; University of Michigan Comprehensive Cancer Center; Medical Oncology, Dana-Farber Cancer Institute; Susan F. Smith Center for Women's Cancers, Dana-Farber Brigham Cancer Center; Harvard Medical School; Mayo; Fox Chase Cancer Center; UPMC Hillman Cancer Center and NRG Oncology; Rogel Cancer Center, University of Michigan Health, Ann Arbor, MI; Exact Sciences; University of Kansas Medical Center Westwood, Westwood, KS, USA; Yale University Cancer Center, New Have, CT, USA; Winship Cancer Institute at Emory University, Atlanta, GA, USA; University of Michigan Medical School. |
|
| 3:00 pm - 3:15 pm CT |
GS1-05 Trial Assigning Individualized Options for Treatment (TAILORx): An update including 12-year event rates
Sparano J, Gray RJ, Makower D, Albain KS, Hayes DF, Geyer C, Dees E, Goetz MP, Olson Jr JA, Lively TG, Badve S, Saphner T, Wagner LI, Whelan T, Kaklamani V, Sledge Jr GW. Mount Sinai Health System, New York, NY, USA; Dana Farber Cancer Institute; Montefiore Medical Center; Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center; University of Michigan Comprehensive Cancer Center; NSABP; UNC Lineberger Cancer Center; Mayo Clinic, Rochester, MN; Washington University in St. Louis School of Medicine; National Cancer Institute; Emory University; Aurora Health; Wake Forest University School of Medicine; McMaster University; University of Texas at San Antonio; Stanford University School of Medicine, Stanford, California. |
|
| 3:15 pm - 3:30 pm CT |
GS1-06 Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial
O'Regan R, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Lang I, Bellet Ezquerra M, Bonnefoi HR, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MM. University of Rochester Medical Center; Biotheranostics, A Hologic Company; The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology; Peter MacCallum Cancer Center, St Vincent’s Hospital, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Breast Cancer Trials Australia & New Zealand, University of Newcastle, Australia; International Breast Cancer Study Group; ETOP EBCSG Partners; European Institute of Oncology IRCCS, and University of Milan, Milan, Italy; Clinexpert0research; Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, and SOLTI Group; Institut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U1312, and European Organisation for Research and Treatment of Cancer (EORTC); Peter MacCallum Cancer Centre, Melbourne, Australia; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS; International Breast Cancer Study Group Statistical Center, Department of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School. |
|
| 3:30 pm - 3:45 pm CT |
GS1-07 Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207
Chavez-MacGregor M, Miao J, Pusztai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Razaq W, O'Dea A, Kaklamani V, Silber ALM, Flaum LE, Andreopolu E, Baar J, Wendt AG, Careny JF, Sharma P, Gralow JR, Lew DL, Barlow WE, Hortobagyi GN. The University of Texas MD Anderson Cancer Center, Houston, TX; Fred Hutchinson Cancer Center; Yale University Cancer Center, New Haven, CT, USA; Mayo Clinic, Rochester, MN; UPMC Hillman Cancer Center and NRG Oncology; UCLA Jonsson Comprehensive Cancer Center, and UCLA Fielding School of Public Health; NRG Oncology and Orlando Health Cancer Institute; NRG Oncology, Division of Pathology, Pittsburgh, PA/NRG Oncology; NRG Oncology Biostatistical Center, University of Pittsburgh, Pittsburgh, PA; Oklahoma University of Health Sciences; University of Kansas Medical Center; University of Texas Health Sciences Center; Yale University; Northwestern University, Chicago, IL; New York Presbyterian/Weill Cornell Medical Center/Columbia University, New York, NY; Case Western Reserve University, Cleveland, OH; Cancer Center at Saint Joseph's, Phoenix AZ; CORA CommonSpirit Health Research Institute; Kaiser Permanente NCORP, Moanalua Medical Center, Honolulu, HI; University of Kansas Medical Center Westwood, Westwood, KA, USA; ASCO; Fred Hutchinson Cancer Research Center; SWOG Statistics and Data Management Center; The University of Texas MD Anderson Cancer Center. |
|
| 3:45 pm - 4:00 pm CT |
GS1-08 Discussant for GS1-06 and GS1-07
Polly Niravath, MD
Houston Methodist Hospital
Houston, TX |
|
| 4:00 pm - 4:15 pm CT |
GS1-09 Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
Johnston S, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, Andre V, Harbeck N, Martín M. The Royal Marsden Hospital; Kyoto University Hospital, Kyoto, Japan; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA; NSABP/NRG Oncology and UPMC Hillman Cancer Center/University of Pittsburgh; Institut de Cancérologie de l'Ouest, René Gauducheau, Saint-Herblain, France; Multidisciplinary Breast Center, University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium; National Taiwan University Hospital; Kantonsspital St.Gallen, Brustzentrum, Departement Interdisziplinäre medizinische Dienste, St. Gallen, Switzerland; Grupo Medico Camino S.C., Mexico City, Mexico; Trakya University Faculty of Medicine, Edirne, Turkey; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Mayo Clinic, Rochester, MN; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland; Instituto do Câncer do Estado de São Paulo (ICESP); University of Genova - IRCCS Ospedale Policlinico San Martino; National Center for Global Health and Medicine; Eli Lilly and Company; Breast Center, Department of Obstetrics and Gynecology, and CCC Munich, LMU University Hospital, Munich, Germany. |
|
| 4:15 pm - 4:30 pm CT |
GS1-10 Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Lu Y-S, Bin Mohd Mahidin EI, Azim H, Eralp Y, Yap Y-S, Im S-A, Rihani J, Bowles J, Delgar Alfaro T, Wu J, Gao M, Slimane K, El Saghir N. National Taiwan University Hospital, Taipei, Taiwan; University of Malaya, Kuala Lumpur, Malaysia; Cairo University, Cairo, Egypt; Istanbul Florence Nightingale Hospital, Istanbul, Turkey; National Cancer Centre Singapore, Singapore; Seoul National University College of Medicine, Seoul, Republic of (South) Korea; King Hussein Cancer Center, Amman, Jordan; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; American University of Beirut Medical Center, Beirut, Lebanon. |
|
| 4:30 pm - 4:45 pm CT |
GS1-11 Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC)
Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F,Gómez Pardo P, Jhaveri K, Delaney R Fu O, Wang H, Verret W, Tolaney SM.
|
|
| 5:00 pm - 6:15 pm CT |
POSTER SESSION 1 and Ongoing Trials Poster Session 1- Hall 1 |
|
| 5:00 pm - 6:15 pm |
SPOTLIGHT POSTER DISCUSSION SESSION 1 - Hemisfair Ballroom 1&2
Racial Outcomes and Disparities
Chair: Vanessa Sheppard, PhD
Virginia Commonwealth University
Richmond, VA
Disparities in screening and outcomes
David Haynes, PhD
University of Minnesota
Minneapolis, MN
Biology, race and outcomes
Elena Martinez, PhD
UC San Diego
San Diego, CA
Patient Perspective
Tammie Denyse, Reverend Dr. (Hon)
Carrie's Touch
Sacramento, CA
|
|
| 5:00 pm - 6:15 pm |
SPOTLIGHT POSTER DISCUSSION SESSION 2 - Stars at Night Ballrooms 1&2
Tumor Immunology and Novel Immune Therapy Strategies
Chair: Cesar Augusto Santa-Maria, MD
Johns Hopkins
Baltimore, MD
Sangeetha Reddy, MD
UT Southwestern Medical Center
Dallas, TX
Justin M. Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN
|
|
| 5:00 pm - 6:15 pm |
SPOTLIGHT POSTER DISCUSSION SESSION 3 - Stars at Night Ballrooms 3&4
New Radiation Techniques
Chair: Richard Zellars, MD
Indiana University
Indianapolis, IN
Is timing everything?
Reshma Jagsi, MD, DPhil
Emory School of Medicine
Atlanta, GA
PBI- Post, Pre and Primary
Ryan M. Rhome, MD, PhD
Indiana University
Indianapolis, IN
|
|
|
OPEN SATELLITE EVENTS |
|
| |
|
|
| 7:00 PM - 9:00 PM CT |
Clarifying the Complexities and Augmenting the Options in the Treatment of HR+/HER2- Breast Cancer: How to Build Better Skills to Make the Most of Existing and Emerging Therapies for the Benefit of Patients With HR+/HER2- MBC and EBC presented by PVI, PeerView Institute for Medical Education
San Antonio Marriott Rivercenter, Salon E, Third Floor
For more information and to register visit our website www.PeerView.com/SanAntonio2022-Live
|
|
| 7:00 PM CT |
Expanding the Spectrum of HER2-Positivity for Precision Breast Cancer Care: Clinical Implications of HER2-Low Status presented by Clinical Care Options, LLC
For more information and to register visit our webiste https://www.clinicaloptions.com/BreastHER2Low2022
|
|
| 7:00 PM CT |
Medical Crossfire®: Clinical Decision Making Under New Paradigms for HR+/HER2-Breast Cancer presented by Physicians' Education Resource, LLC
For more information and to register visit our website https://event.gotoper.com/event/14ff9bd7-7829-467c-afb4-6638328c0010/summary
|
|
|
|